High efficiency of benzoporphyrin derivative in the photodynamic therapy of pigmented malignant melanoma

British Journal of Cancer

Volumn 79, Issue 5-6, 1999, Pages 821-824

  Busetti, A ^b   Soncin, M ^c   Jori, G ^c   Rodgers, M A J ^a  

^a BOWLING GREEN STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PADOVA   (Italy)

^c NONE

Author keywords

Benzoporphyrin derivative; Photodynamic therapy; Pigmented melanoma

Indexed keywords

BENZOPORPHYRIN DERIVATIVE; PHOTOSENSITIZING AGENT;

ANIMAL EXPERIMENT; ARTICLE; FEMALE; INTRAVENOUS DRUG ADMINISTRATION; MELANOMA; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR NECROSIS;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIVISION; FEMALE; LIGHT; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NECROSIS; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; TIME FACTORS; TISSUE DISTRIBUTION;

EID: 0033001920     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690131     Document Type: Article

References (15)

1. Allison BA, Waterfield E, Richter AM and Levy JG (1991) The effects of plasma lipoproteins on in vitro tumor cell killing and in vivo tumor photosensitization with benzoporphyrin derivative. Photochem Photobiol 54: 709-715
2. Biolo R, Jori G, Soncin M, Pratesi R, Vanni U, Rihter B, Kenney ME and Rodgers MAJ (1994) Photodynamic therapy of B16 pigmented melanoma with liposome-delivered Si(IV)-naphthalocyanine. Photochem Photobiol 59: 362-365
3. Biolo R, Jori G, Soncin M, Rihter M, Kenney ME and Rodgers MAJ (1996) Effect of photosensitizer delivery system and irradiation parameters on the efficiency of photodynamic therapy of B16 pigmented melanoma. Photochem Photobiol 63: 224-228
4. Busetti A, Soncin M, Jori G, Kenney ME and Rodgers MAJ (1998) Treatment of cutaneous malignant melanoma by high peak power 1,064 nm irradiation followed by photodynamic therapy. Photochem Photobiol 8: 377-381
5. Cuomo V, Jori G, Rihter B, Kenney ME and Rodgers MAJ (1990) Liposome-delivered Si(IV)-naphthalocyanine as a photodynamic sensitizer for experimental tumours: pharmacokinetic and phototherapeutic studies. Br J Cancer 62: 966-970
6. Dougherty TJ (1987) Photosensitizers: therapy and detection of malignant tumours. Photochem Photobiol 45: 879-889
7. Jori G (1987) Photodynamic therapy of solid tumours. Radiat Phys Chem 30: 375-380
8. Levy S (1996) New applications in photodynamic therapy. Photochem Photobiol 64: 737-739
9. Levy JG, Waterfield E, Richter AM, Smits C, Lui H, Hruza L and Anderson RR (1994) Photodynamic therapy of malignancies with benzoporphyrin derivative monoacid ring A. In Photodynamic Therapy of Cancer, Vol. 2,074. Jori G, Moan J and Star WN (eds), pp. 91-101. SPIE: Bellingham, WA
10. Marcus S (1992) Clinical photodynamic therapy: the continuing evolution. In Photodynamic Therapy: Basic Principles and Clinical Application. Henderson BW and Dougherty TJ (eds), pp. 219-268. Marcel Dekker: New York
11. Richter AM, Cerruti-Sola S, Sternberg ED, Dolphin D and Levy JG (1990) Biodistribution of tritiated benzoporphyrin derivative, a new potent photosensitizer in normal and tumour-bearing mice. J Photochem Photobiol B: Biol 5: 231-244
12. Schuitmaker JJ, van Best JA, van Delft JL, Jannink JE, Oosterhuis JA, Vrensen GFJM, de Wolff-Rouendaal D and Dubbelman TMAR (1995) Photodynamic therapy of hamster greene melanoma in vitro and in vivo using Bacteriochlorin a as photosensitizer. In Photochemotherapy: Photodynamic Therapy and Other Modalities, Vol. 2,625. Ehrenberg B, Jori G and Moan J (eds), pp. 251-260. SPIE: Bellingham, WA
13. Svaasand LO, Martinelli E, Gomer CJ Profio AE (1990) Optical characteristics of intraocular tumours in the visible and near infrared. In Photodynamic Therapy: Mechanisms II, Vol. 1,203. Dougherty TJ and Katzir A (eds), pp. 2-21. SPIE: Bellingham, WA
14. Woodburn W, Qing F, Kessel D, Luo Y and Young W (1997) Photodynamic therapy of pigmented melanoma with Lutetium Texaphyrin. Photochem Photobiol 65: 59S
15. Wosko TJ, Ferrara DT and Sartori TS (1994) Histological comparison of the B16 melanoma and its FI variant. Cancer Lett 24: 57-63